Therapeutic vaccination and novel strategies to treat chronic HBV infection

References

• Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med.359, 1486–1500 (2008).
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol.39(1), 115–124 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol.145, 3442–3449 (1990).
   PubMed Web of Science ®Google Scholar
• Jung M, Spengler U, Schraut W et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol.13, 310–317 (1991).
   PubMed Web of Science ®Google Scholar
• Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest.98(5), 1185–1194 (1996).
   PubMed Web of Science ®Google Scholar
• Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology25(4), 1022–1027 (1997).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med.181(3), 1047–1058 (1995).
   PubMed Web of Science ®Google Scholar
• Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J. Exp. Med.174(6), 1565–1570 (1991).
   PubMed Web of Science ®Google Scholar
• Jung M, Hartmann B, Gerlach J et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology261, 165–172 (1999).
   PubMed Web of Science ®Google Scholar
• Tan AT, Loggi E, Boni C et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J. Virol.82(22), 10986–10997 (2008).
   PubMed Web of Science ®Google Scholar
• Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest.102(5), 968–975 (1998).
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol.39(4), 595–605 (2003).
   PubMed Web of Science ®Google Scholar
• Cooksley H, Chokshi S, Wedemeyer H et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil treatment: a multicentre controlled study. J. Hepatol.36(Suppl. 1), 7 (2002).
   Google Scholar
• Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology104(6), 1818–1821 (1993).
   PubMed Web of Science ®Google Scholar
• Lau GK, Lok AS, Liang RH et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology25(6), 1497–1501 (1997).
   PubMed Web of Science ®Google Scholar
• Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology122(3), 614–624 (2002).
   PubMed Web of Science ®Google Scholar
• Loggi E, Bihl F, Chisholm III JV et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J. Hepatol.50, 625–630 (2009).
   PubMed Web of Science ®Google Scholar
• Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol.76(11), 5305–5314 (2002).
   PubMed Web of Science ®Google Scholar
• Rollier C, Sunyach C, Barraud L et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology116, 658–665 (1999).
   PubMed Web of Science ®Google Scholar
• Pol S, Nalpas B, Driss F et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol.34(6), 917–921 (2001).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Lau GKK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by anti-viral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine25, 8585–8597 (2007).
   PubMed Web of Science ®Google Scholar
• Lu M, Yao X, Xu Y et al. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J. Virol.82(5), 2598–2603 (2008).
   PubMed Web of Science ®Google Scholar
• Jung MC, Gruner N, Zachoval R et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine20(29–30), 3598–3612 (2002).
   PubMed Web of Science ®Google Scholar
• Rahaman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscolar vaccination with the major hepatitis B surface antigen. Hepatology31(2), 521–527 (2000).
   PubMed Web of Science ®Google Scholar
• Heathcote J, McHutchison J, Lee S et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology30, 531–536 (1999).
   PubMed Web of Science ®Google Scholar
• Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest.95(1), 341–349 (1995).
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology40(4), 874–882 (2004).
   PubMed Web of Science ®Google Scholar
• Yang SH, Lee CG, Im SJ et al. Correlation of antiviral T cell responses with supression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther.13, 1110–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Akbar SM, Murakami H, Horiike N, Onji M. Dendritic cell-based therapies in the bench and the bedsides. Curr. Drug Targets Inflamm. Allergy3(3), 305–310 (2004).
   PubMedGoogle Scholar
• Xu DZ, Zhao K, Guo LM et al. A randomized controlled Phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE3(7), e2565 (2008).
   PubMed Web of Science ®Google Scholar
• Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine25(10), 1771–1779 (2007).
   PubMed Web of Science ®Google Scholar
• Lin YC, Chang MH, Ni YH, Hsu CH, Chen DS. Long term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis.187, 134–138 (2003).
   PubMed Web of Science ®Google Scholar
• Beasley RP, Lee CK, Roan CH et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet2(8359), 1099–1102 (1983).
   PubMed Web of Science ®Google Scholar
• Baht P, Anderson DA. Hepatitis B virus translocates across a trophoblastic barrier. J. Virol.81, 7200–7207 (2007).
   PubMed Web of Science ®Google Scholar
• Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J. Pediatr.133, 374–377 (1998).
   PubMed Web of Science ®Google Scholar
• Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J. Viral Hepatitis16, 94–103 (2009).
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol.77(8), 4911–4927 (2003).
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity27, 670–684 (2007).
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol.81(8), 4215–4225 (2007).
   PubMed Web of Science ®Google Scholar
• Lopes AR, Kellam P, Das A et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest.118(5), 1835–1845 (2008).
   PubMed Web of Science ®Google Scholar
• Gehring A, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology137(2), 682–690 (2009).
   PubMed Web of Science ®Google Scholar
• Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol.76(17), 8609–8620 (2002).
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol.78(11), 5707–5719 (2004).
   PubMed Web of Science ®Google Scholar
• Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich D. The serology of chronic hepatitis B infection revisited. J. Clin. Invest.91, 2586–2595 (1993).
   PubMed Web of Science ®Google Scholar
• van Driel I, Ang D. The role of regulatory T cells in gastrointestinal inflammatory disease. J. Gastroenterol. Hepatol.23(2) 171–177 (2008).
   PubMed Web of Science ®Google Scholar
• Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J. Virol.82(1), 21–30 (2007).
   PubMed Web of Science ®Google Scholar
• Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis.7(12), 804–813 (2007).
   PubMed Web of Science ®Google Scholar
• Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl.13(3), 434–442 (2007).
   PubMed Web of Science ®Google Scholar
• Yang G, Liu A, Xie Q et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int. Immunol.19(2), 133–140 (2007).
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kobayashi K, Ueno Y et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J. Gastroenterol.12(27), 4310–4317 (2006).
   PubMed Web of Science ®Google Scholar
• Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J. Virol.79(6), 3322–3328 (2005).
   PubMed Web of Science ®Google Scholar
• Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol.177(1), 739–747 (2006).
   PubMed Web of Science ®Google Scholar
• Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology41(4), 771–778 (2005).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol.18, 767–811 (2000).
   PubMed Web of Science ®Google Scholar
• Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J. Virol.75(4), 1770–1782 (2001).
   PubMed Web of Science ®Google Scholar
• Tavakoli S, Schwerin W, Rohwer A et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J. Gen. Virol.85(Pt 10), 2829–2836 (2004).
   PubMed Web of Science ®Google Scholar
• Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology43(3), 539–547 (2006).
   PubMed Web of Science ®Google Scholar
• Wang FS, Xing LH, Liu MX et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J. Gastroenterol.7(4), 537–541 (2001).
   PubMed Web of Science ®Google Scholar
• Beckebaum S, Cicinnati VR, Dworacki G et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin. Immunol.104(2), 138–150 (2002).
   PubMed Web of Science ®Google Scholar
• Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B – restoration by exogenous interleukin-12. Clin. Exp. Immunol.130(1), 107–114 (2002).
   PubMed Web of Science ®Google Scholar
• van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology40(3), 738–746 (2004).
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol.178(10), 6634–6641 (2007).
   PubMed Web of Science ®Google Scholar
• Das A, Hoare M, Davies N et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med.205(9), 2111–2124 (2008).
   PubMed Web of Science ®Google Scholar
• Sällberg M, Hughes J, Javadian A et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther.9, 1719–1729 (1998).
   PubMed Web of Science ®Google Scholar
• Depla E, van der Aa A, Livingston B et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J. Virol.82, 435–450 (2008).
   PubMed Web of Science ®Google Scholar
• Riedl P, Bertoletti A, Lopes R, Lemonnier F, Reimann J, Schirmbeck R. Distinct, cross-reactive epitope specificities of CD8 T cell responses are induced by natural hepatitis B surface antigen variants of different hepatitis B virus genotypes. J. Immunol.176, 4003–4011 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamoto N, Cho H, Shaked A et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PloS Pathogens5(2), e1000313 (2009).
   PubMed Web of Science ®Google Scholar
• Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature458(7235), 206–210 (2009).
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol.8, 239–245 (2007).
   PubMed Web of Science ®Google Scholar
• Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology134, 239–247 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314, 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology100, 182–188 (1991).
   PubMed Web of Science ®Google Scholar
• Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol.27, 572–577 (1997).
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J. Med. Virol.65, 473–477 (2001).
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol.62, 299–307 (2000).
   PubMed Web of Science ®Google Scholar
• Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J. Hepatol.28, 359–368 (1998).
   PubMed Web of Science ®Google Scholar
• Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood100, 391–396 (2002).
   PubMed Web of Science ®Google Scholar
• Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology36(3), 702–709 (2002).
   PubMed Web of Science ®Google Scholar